Maryland-made breast cancer treatment system gets FDA clearance - Technical.ly Baltimore

Sciences

Jan. 8, 2018 12:57 pm

Maryland-made breast cancer treatment system gets FDA clearance

After years of development from the University of Maryland School of Medicine and a Columbia-based company, the GammaPod will be used for treatment in Baltimore in 2018.

A rendering of the GammaPod.

(Courtesy photo)

This post was updated at 5:20 p.m. on 1/8/2018.

After nearly a decade in development, a device to treat breast cancer that was developed at the University of Maryland School of Medicine has a key clearance toward going to market.

The U.S. Food and Drug Administration gave a 510(k) medical device clearance to the GammaPod, a device which treats early-stage breast cancer. The announcement was made in December.

“During radiation therapy, tumor cells are killed when their DNA is damaged by the radiation being absorbed into them. While radiation therapy has the potential to kill tumor cells, it can also damage healthy tissue around the tumor,” the FDA stated.

GammaPod requires patients to lie on their stomach. According to the University of Maryland-Baltimore, the device delivers a high dose of radiation to a tumor, but  keeps radiation from getting to normal breast tissue and other organs.

“GammaPod uses thousands of focused beams of radiation from 36 rotating radioactive Cobalt-60 sources in combination with a two-layer, vacuum-assisted cup that immobilizes the breast to achieve a more accurate delivery of radiation,” the FDA states.

It is not designed to replace Whole Breast Radiation Therapy, but the device could also reduce the time of the more targeted treatments from many weeks to less than a week.

“The GammaPod delivers a uniform dose to the tumor but the amount of radiation drops off rapidly outside the targeted area with a substantially reduced dose to healthy breast tissue,” Elizabeth M. Nichols, an assistant professor of radiation oncology at UMSOM who led a feasibility and safety study of the device in 2016, said in a statement. “We believe that this reduced exposure will result in better cosmetic outcomes for patients.”

Advertisement

The path for the device to date shows one local pathway toward bringing such a device to market. The GammaPod was invented by scientists at the University of Maryland School of Medicine in Baltimore including radiation oncology professor William F. Regine. The prototype was tested at the University of Maryland Medical Center. Columbia-based Xcision Medical Systems handled manufacturing, and applied for the FDA clearance to bring the device to market.

While clinical trials will continue to investigate further uses, the first treatment is expected to be offered at UM Medical Center in spring 2018.

-30-
LEAVE A COMMENT

Advertisement

This company is prototyping an unmanned health clinic in Baltimore

How Harpoon Medical’s exit can produce returns for Baltimore

Harpoon Medical’s Baltimore office will remain intact following acquisition

SPONSORED

Baltimore

How Think|Stack and Year Up are cultivating local tech talent

Baltimore

Datastory Consulting

Sales Representative

Apply Now
Baltimore

SmartLogic

Developer

Apply Now
Baltimore

Terbium Labs

Analyst

Apply Now

How 3D printing could help treat hearing loss

How NIH is responding to the opioid crisis, locally and nationally

Gates Foundation backs JHU team developing sensors to monitor newborns’ health

SPONSORED

Baltimore

Let these free workshops help your business really take off

Owings Mills, Maryland

Mind Over Machines

Consultant (Software Developer)

Apply Now
Baltimore

Protenus

Data Engineer

Apply Now
Baltimore

Protenus

Front-End Developer

Apply Now

Sign-up for regular updates from Technical.ly

Do NOT follow this link or you will be banned from the site!